BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15056732)

  • 1. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells.
    Buck MB; Pfizenmaier K; Knabbe C
    Mol Endocrinol; 2004 Jul; 18(7):1643-57. PubMed ID: 15056732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
    Joffroy CM; Buck MB; Stope MB; Popp SL; Pfizenmaier K; Knabbe C
    Cancer Res; 2010 Feb; 70(4):1314-22. PubMed ID: 20145137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
    Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation.
    Giehl K; Seidel B; Gierschik P; Adler G; Menke A
    Oncogene; 2000 Sep; 19(39):4531-41. PubMed ID: 11002426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.
    Buck MB; Coller JK; Mürdter TE; Eichelbaum M; Knabbe C
    Breast Cancer Res Treat; 2008 Jan; 107(1):15-24. PubMed ID: 18043895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
    Varma H; Conrad SE
    Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo.
    Kamaraju AK; Roberts AB
    J Biol Chem; 2005 Jan; 280(2):1024-36. PubMed ID: 15520018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells.
    Tong GM; Rajah TT; Zang XP; Pento JT
    Anticancer Res; 2002; 22(1A):103-6. PubMed ID: 12017270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
    Hui R; Finney GL; Carroll JS; Lee CS; Musgrove EA; Sutherland RL
    Cancer Res; 2002 Dec; 62(23):6916-23. PubMed ID: 12460907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
    Herman ME; Katzenellenbogen BS
    J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
    McClelland RA; Barrow D; Madden TA; Dutkowski CM; Pamment J; Knowlden JM; Gee JM; Nicholson RI
    Endocrinology; 2001 Jul; 142(7):2776-88. PubMed ID: 11415996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.